Trial
NCT00088907
Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Recurrent Head and Neck Cancer
Intervention
docetaxel
Why stopped
It was unlikely that the primary endpoint would be reached based on the fifth interim analysis results.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-05-06